FDG PET/CT in differentiated thyroid cancer patients with low thyroglobulin levels

Autor: Chantal A Lebbink, Lisa H de Vries, Inne H M Borel Rinkes, Arthur J A T Braat, Rachel S van Leeuwaarde, Lutske Lodewijk, Mark J C van Treijen, Menno R Vriens, Gerlof D Valk, Hanneke M van Santen, Bart de Keizer
Rok vydání: 2022
Předmět:
Zdroj: European journal of endocrinology. 187(1)
ISSN: 1479-683X
Popis: Objective To evaluate the usefulness of [18F]fluorodeoxyglucose (FDG) positron emissive tomography (PET)/CT in patients with low detectable thyroglobulin levels suspicious for persistent or recurrent differentiated thyroid cancer (DTC). Methods A retrospective case series study evaluating FDG PET/CT in patients with detectable thyroglobulin (Tg) levels (≥0.20 and Results Twenty-seven patients underwent FDG PET/CT. Median Tg level at FDG PET/CT was 2.00 ng/mL (range 0.30–9.00). FDG PET/CT was positive in 14 patients (51.9%): lesions suspicious for lymph node metastases were depicted in 12 patients, and lung metastases in 2. DTC was confirmed in 13/14 FDG PET/CT-positive patients. In 9/13 patients with a negative FDG PET/CT, DTC was confirmed ≤3 months after FDG PET/CT. The sensitivity, PPV, specificity and NPV were 59.1, 92.9, 80.0 and 30.8%, respectively. Conclusions This case series shows that FDG PET/CT might be useful to detect persistent or recurrent DTC in patients with low detectable Tg. However, when FDG PET/CT is negative, this does not rule out DTC and further investigations are necessary.
Databáze: OpenAIRE